A protein called METTL1 causes fatty liver disease by modifying how cells read genetic instructions for another protein called ALOX15B, according to Gram Research analysis. When METTL1 levels are high, it makes ALOX15B more active, triggering a chain reaction that leads to fat accumulation in liver cells. Scientists found that removing METTL1 significantly reduced fat buildup in liver cells, while adding extra METTL1 made the problem worse.
Scientists discovered that a protein called METTL1 plays a major role in causing fatty liver disease by modifying how cells read genetic instructions. When METTL1 levels are high, it makes another protein called ALOX15B more active, which leads to fat accumulating in liver cells. According to Gram Research analysis, this discovery could lead to new treatments for metabolic dysfunction-associated steatotic liver disease (MASLD), a condition affecting millions of people worldwide. The research was conducted in lab cells, mice, and human liver samples, showing consistent results across different models of fatty liver disease.
Key Statistics
A 2026 research study published in Life Sciences found that METTL1 protein levels were significantly elevated in fatty liver tissue from both humans with metabolic dysfunction-associated steatotic liver disease and mice fed a high-fat diet compared to healthy controls.
When researchers removed METTL1 from liver cells exposed to free fatty acids, the cells accumulated markedly less fat, demonstrating that METTL1 is necessary for the fat accumulation that characterizes fatty liver disease.
The study identified that METTL1 promotes hepatic steatosis by depositing m7G chemical modifications on ALOX15B messenger RNA, which increases ALOX15B protein levels and activates the ERK1/2 cellular signaling pathway.
When scientists artificially increased ALOX15B expression in cells where METTL1 had been removed, fat accumulation returned to high levels, proving that ALOX15B is the key target through which METTL1 causes fatty liver disease.
The Quick Take
- What they studied: How a protein called METTL1 causes fat to build up in liver cells by changing how genetic instructions are read
- Who participated: Laboratory liver cells (both mouse and human types), mice fed a high-fat diet, and liver tissue samples from people with fatty liver disease
- Key finding: When METTL1 is turned off, liver cells accumulate much less fat. When it’s turned on, fat accumulation gets worse. METTL1 works by modifying another protein called ALOX15B, which then triggers a chain reaction that leads to fat storage
- What it means for you: This research identifies a potential new target for treating fatty liver disease. However, these are early-stage findings from lab and animal studies, so human treatments are still years away. If you have fatty liver disease, current lifestyle changes like diet and exercise remain your best options
The Research Details
This research used multiple approaches to understand how METTL1 causes fatty liver disease. First, scientists examined liver tissue from people with fatty liver disease and compared it to healthy liver tissue, finding that METTL1 levels were much higher in diseased livers. They then used laboratory-grown liver cells from both mice and humans, exposing them to free fatty acids to mimic the disease in a dish. To understand METTL1’s role, they created cells with extra METTL1 (overexpression) and cells with METTL1 removed (knockdown), then measured how much fat accumulated in each. They also used advanced genetic sequencing to identify which genes METTL1 affects and confirmed their findings using specialized techniques to track how METTL1 modifies specific messenger RNA molecules. Finally, they tested their findings in mice fed a high-fat diet to see if the results held true in a living organism.
This multi-layered approach is important because it moves from observation (finding high METTL1 in diseased livers) to cause-and-effect proof (showing that removing METTL1 prevents fat buildup). By testing in cells, animals, and human tissue, the researchers demonstrated that their findings are likely relevant to real human disease. The use of genetic sequencing and molecular tracking techniques allowed them to identify the exact mechanism—how METTL1 modifies ALOX15B—rather than just observing that METTL1 is involved.
The study’s strength lies in its consistent findings across multiple model systems (cells, mice, and human samples). The researchers used both gain-of-function (adding more METTL1) and loss-of-function (removing METTL1) experiments, which strengthens their conclusions. However, the study was conducted primarily in laboratory settings, which means the findings need to be confirmed in human clinical trials before they can be used as treatments. The sample size for human liver samples was not specified in the abstract, which is a limitation. The research was published in Life Sciences, a peer-reviewed journal, indicating it passed scientific review.
What the Results Show
The research revealed a clear chain of events in fatty liver disease. First, METTL1 protein levels are significantly elevated in fatty livers compared to healthy livers in both humans and mice. When scientists removed METTL1 from liver cells exposed to free fatty acids, the cells accumulated much less fat—demonstrating that METTL1 is necessary for fat buildup. Conversely, when they added extra METTL1 to cells, fat accumulation worsened. The key mechanism involves METTL1 modifying ALOX15B messenger RNA (the genetic instruction for making ALOX15B protein) through a chemical modification called m7G. This modification makes the ALOX15B messenger RNA more stable and longer-lasting, leading to higher levels of ALOX15B protein. Higher ALOX15B protein then activates a cellular signaling pathway called ERK1/2, which ultimately promotes fat storage in liver cells.
When researchers artificially increased ALOX15B expression in cells where METTL1 had been removed, the fat accumulation returned to high levels. This finding was crucial because it proved that ALOX15B is the key target through which METTL1 causes fatty liver disease. The research also showed that the METTL1-ALOX15B relationship holds true across different cell types and disease models, suggesting this mechanism is a fundamental driver of the disease rather than an isolated finding.
This research builds on growing evidence that epitranscriptomic modifications—chemical changes to RNA that don’t alter the genetic code itself—play important roles in liver disease. Previous studies had identified other epitranscriptomic modifications in fatty liver disease, but the specific role of m7G modification through METTL1 was previously unknown. This work fills an important gap by identifying a new regulatory mechanism and a potential new drug target that hadn’t been clearly connected to fatty liver disease before.
The study has several important limitations. Most experiments were conducted in laboratory cells or mice, not in living humans, so the findings need confirmation in human clinical trials. The exact sample size of human liver samples wasn’t specified. The research focused on one specific protein pathway, so there are likely other mechanisms contributing to fatty liver disease that weren’t addressed. Additionally, while the study shows that METTL1 causes fat accumulation, it doesn’t address whether reducing METTL1 in people with existing fatty liver disease would actually improve their condition—that would require human studies. The research also doesn’t explain why METTL1 levels become elevated in the first place.
The Bottom Line
Based on this research, there are no immediate changes to recommend for people with fatty liver disease, as these findings are still in the laboratory stage. However, this research identifies METTL1 as a potential drug target, meaning pharmaceutical companies may develop medications that block METTL1 in the future. In the meantime, established treatments for fatty liver disease remain effective: weight loss (even 5-10% of body weight helps), reducing refined carbohydrates and added sugars, limiting alcohol, and increasing physical activity. These lifestyle changes address multiple pathways in the disease, not just METTL1. Confidence level: High for lifestyle recommendations; Low for METTL1-targeting treatments (not yet available).
This research is most relevant to people with metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease. It’s also important for researchers developing new treatments and for people at risk of fatty liver disease (those with obesity, type 2 diabetes, or metabolic syndrome). Healthcare providers treating fatty liver disease should be aware of this emerging target. People without fatty liver disease don’t need to take action based on this research alone.
If METTL1-targeting drugs are developed, they would typically require 5-10 years of clinical trials before becoming available to patients. Even then, they would likely be used alongside lifestyle changes, not as replacements. For now, lifestyle modifications can show improvements in liver fat content within 3-6 months of consistent effort.
Frequently Asked Questions
What is METTL1 and why does it cause fatty liver disease?
METTL1 is a protein that modifies how cells read genetic instructions. It causes fatty liver disease by modifying ALOX15B messenger RNA, making it more stable and increasing ALOX15B protein levels, which then triggers fat storage in liver cells.
Can I get a drug that blocks METTL1 to treat my fatty liver?
Not yet. This research identifies METTL1 as a potential drug target, but medications targeting it are still in development. Current proven treatments include weight loss, reducing sugar and refined carbohydrates, limiting alcohol, and increasing exercise.
Does this research mean my fatty liver disease is caused by high METTL1?
High METTL1 is one important mechanism in fatty liver disease, but not the only cause. Fatty liver disease involves multiple pathways, including insulin resistance, inflammation, and metabolic dysfunction. This research identifies one piece of a complex puzzle.
How long until METTL1-blocking treatments will be available?
If pharmaceutical companies develop METTL1-targeting drugs, they would typically require 5-10 years of clinical trials before becoming available to patients. This research is still in early stages and needs human testing first.
Should I change my diet based on this METTL1 research?
This specific research doesn’t suggest new dietary changes, but established treatments for fatty liver disease remain effective: reduce refined carbohydrates and added sugars, lose 5-10% of body weight, limit alcohol, and increase physical activity.
Want to Apply This Research?
- Track weekly weight changes and monthly liver enzyme levels (ALT and AST) if you have fatty liver disease. These are measurable markers that reflect liver health and can show whether interventions are working.
- Set a specific goal to reduce refined carbohydrates and added sugars by 25% this week, and increase daily steps by 2,000. Log these changes daily in the app to build awareness of how diet and activity affect your liver health.
- Create a monthly check-in to review weight trends, energy levels, and any lab work results. Set reminders for regular doctor visits to monitor liver enzymes (ALT, AST, and GGT). Use the app to track which dietary changes and exercise routines correlate with the best health markers.
This research is from laboratory and animal studies and has not yet been tested in human clinical trials. The findings identify a potential drug target but do not represent an approved treatment. If you have fatty liver disease or metabolic dysfunction-associated steatotic liver disease, consult your healthcare provider about evidence-based treatment options including lifestyle modifications and medical management. Do not make changes to your treatment plan based solely on this research. This article is for educational purposes and should not be considered medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.